Teleflex (TFX) Receives FDA Nod For Expanded Use Of UroLift
Zacks Investment Research | Jan 09, 2020 08:38PM ET
Teleflex Incorporated (NYSE:TFX) recently received the FDA’s clearance for expanded indication for the use of the UroLift System to treat larger prostates (between 80cc and 100cc). With the recent approval for the expanded use of the UroLift System, Teleflex aims at fortifying its position in the Interventional Urology business on a global scale.
The UroLift System, a minimally invasive in-office treatment, can be used for faster treatment and recovery from the symptoms of benign prostatic hyperplasia (BPH). Teleflex’s UroLift System’s expanded use has also received a steady support from the medical fraternity.
Significance of the Approval
BPH or enlarged prostate is a non-cancerous enlargement of prostate in older men, affecting more than 40 million people in the United States alone. If the symptoms of BPH are not treated on time, the condition can worsen, even resulting in permanent bladder damage. With the recent clearance for the expanded use of the UroLift System, more patients can be brought under the purview of the treatment offered by Teleflex.
The collection of data presented to the FDA has certified the UroLift System treatment to be safe and effective for men with prostate sizes between 80cc and 100cc. The outcome of this data is similar to the L.I.F.T. randomized controlled trial, which showed that almost 70% of the patients with BPH belonged to the drug dropout category. Per Teleflex, there are no apparent differences in reported adverse events, thus indicating a comparable safety profile.
Industry Prospects
Per a report by Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.